Search results
Results From The WOW.Com Content Network
Patiromer was generally well tolerated in studies. Side effects that occurred in more than 2% of patients included in clinical trials were mainly gastro-intestinal problems such as constipation, diarrhea, nausea, and flatulence, and also hypomagnesemia (low levels of magnesium in the blood) in 5% of patients, because patiromer binds magnesium in the gut as well.
Hyperkalemia is an elevated level of potassium (K +) in the blood. [6] [1] Normal potassium levels are between 3.5 and 5.0 mmol/L (3.5 and 5.0 mEq/L) with levels above 5.5 mmol/L defined as hyperkalemia. [3] [4] Typically hyperkalemia does not cause symptoms. [1] Occasionally when severe it can cause palpitations, muscle pain, muscle weakness ...
However, if hyperkalemia causes any ECG change it is considered a medical emergency [12] due to a risk of potentially fatal abnormal heart rhythms and is treated urgently. [12] Potassium levels greater than 6.5 to 7.0 mmol/L in the absence of ECG changes are managed aggressively. [12] Several approaches are used to treat hyperkalemia. [12]
Apples. The original source of sweetness for many of the early settlers in the United States, the sugar from an apple comes with a healthy dose of fiber.
Importantly, the use of the potassium-enriched salt substitute did not significantly increase the risk of high potassium levels (hyperkalemia). How salt substitutes work to lower stroke risk
High blood pressure is caused by the force of blood flow in the arteries being too high. The DASH diet includes heart-healthy foods that lower blood pressure.
Potassium binders are medications that bind potassium ions in the gastrointestinal tract, thereby preventing its intestinal absorption. This category formerly consisted solely of polystyrene sulfonate, a polyanionic resin attached to a cation, administered either orally or by retention enema to patients who are at risk of developing hyperkalaemia (abnormal high serum potassium levels).
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.